In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. IV. Cytotoxic effect of an anti-T11-gelonin immunotoxin.
The cytotoxic effect of a lymphocyte-specific immunotoxin formed by disulfide conjugation of an anti-T11 monoclonal antibody with the ribosome-inactivating protein gelonin was assessed in vitro on peripheral blood T cells and in vivo on splenic and lymph node T cells of macaque monkeys. This immunotoxin was cytotoxic to proliferating peripheral blood T cells in vitro as measured by both direct and indirect assays. Two sequential intravenous infusions into macaque monkeys achieved plasma concentrations of immunotoxin far in excess of those shown to be cytotoxic for cultured T cells and coated all T cells in lymph nodes and spleen with intact immunotoxin for four days. However, the cytotoxic effect of the immunotoxin on T cells in vivo was considerably less than that predicted by the in vitro studies. Further experiments suggested that the state of activation of the targeted T cell population in vivo, or the appearance of anti-immunotoxin antibodies, which occurred in all infused monkeys, might attenuate immunotoxin-mediated cell killing in vivo. These studies illustrate the significant differences between the action of immunotoxin conjugates in vitro, and those seen when these conjugates are utilized as therapeutic agents in vivo.
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000096:biosynthesis; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000633:toxicity; D000918:Antibody Specificity; D000943:Antigens, Differentiation / Q000276:immunology*; D000961:Antilymphocyte Serum / Q000008:administration & dosage* / Q000633:toxicity; D001790:Blood Physiological Phenomena; D018801:CD2 Antigens; D003601:Cytotoxicity Tests, Immunologic; D003603:Cytotoxins / Q000008:administration & dosage / Q000633:toxicity; D004355:Drug Stability; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000633:toxicity; D000922:Immunotoxins / Q000008:administration & dosage* / Q000633:toxicity; D007399:Interphase / Q000187:drug effects; D008213:Lymphocyte Activation / Q000187:drug effects; D008252:Macaca fascicularis; D051379:Mice; D010940:Plant Proteins / Q000633:toxicity*; D011971:Receptors, Immunologic / Q000276:immunology*; D054789:Ribosome Inactivating Proteins, Type 1; D013601:T-Lymphocytes / Q000276:immunology*; D013936:Thymidine / Q000037:antagonists & inhibitors
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D000943:Antigens, Differentiation; D000961:Antilymphocyte Serum; D018801:CD2 Antigens; D003603:Cytotoxins; D007166:Immunosuppressive Agents; D000922:Immunotoxins; D010940:Plant Proteins; D011971:Receptors, Immunologic; D054789:Ribosome Inactivating Proteins, Type 1; C025674:GEL protein, Gelonium multiflorum; D013936:Thymidine